Study of Modified FOLFIRINOX in Advanced Pancreatic Cancer


Metastatic Pancreatic Cancer | Pancreatic Cancer

What is the purpose of this trial?

The primary objective of this study is to determine the progression free survival in patients with metastatic pancreatic cancer and in patients with locally advanced unresectable non-metastatic pancreatic cancer treated with a dose-attenuated modification of folinic acid, fluorouracil, irinotecan, and oxaliplatin (FOLFIRINOX). Secondary endpoints include: determine objective response rate according to RECIST; determine overall survival; evaluate toxicity; determine rate of resection in locally advanced unresectable stratum; correlate time to progression, objective response, and overall survival with early changes in glucose metabolism using [18F]-fluorodeoxyglucose (FDG)-positron emission tomography (PET) scanning.

Participation Guidelines

18 Years - N/A

Click here for detailed information about who can participate in this trial.

Yale University
October 2011
Last Updated:
May 19, 2014
Study HIC#:

Clinicaltrials.gov ID: NCT01523457